July 28th 2011
It had been thought that removing the sentinel node and the surrounding lymph nodes would improve survival rates.
July 21st 2011
The NCCN voted to maintain the current recommendation and position on Avastin (bevacizumab) in its treatment of metastatic breast cancer.
July 14th 2011
Study results reveal that only a small fraction of patients with high-grade, noninvasive bladder cancer receive the appropriate treatment.
July 7th 2011
Almost 1 in 3 adults in the United States do not get screened regularly.
June 30th 2011
Patients screened with low-dose helical computed tomography (CT) reduced their risk of dying of lung cancer by 20% compared with chest x-ray.
June 23rd 2011
Shortages of chemotherapy drugs continue to plague the healthcare industry.
June 16th 2011
The FDA announced that the prolonged use of pioglitazone (Actos) for more than 1 year has been linked to an increased risk of bladder cancer
June 10th 2011
Primary cancers of the lung, esophagus, and pancreas-all of which have a poor prognosis-account for >35% of all cancer deaths in the United States annually
June 2nd 2011
An experimental melanoma vaccine gp100 peptide vaccine in combination with IL2 may shrink tumors and prevent the progression of late-stage melanoma
June 1st 2011
Highlights on updates to the clinical practice guidelines from the annual National Comprehensive Cancer Network (NCCN) conference
May 26th 2011
Men with advanced CRPC who were treated with abiraterone acetate plus prednisone/prednisolone had significant improvement in overall survival
May 24th 2011
Interview with Patricia Goldsmith the executive vice president and chief operating officer of the National Comprehensive Cancer Network (NCCN)
May 24th 2011
Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.
May 19th 2011
Crizotinib was accepted for filing by the FDA and granted Priority Review status
May 18th 2011
The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound
May 12th 2011
Results from a phase III study showed that the chemotherapy combination FOLFIRINOX nearly doubled the survival time for patients with pancreatic adenocarcinoma
May 5th 2011
Reimbursement is often insufficient to cover the purchase cost of cancer drugs, forcing oncologists to pay out of pocket to treat patients
April 28th 2011
A class of drugs that has shown encouraging results in breast and ovarian cancers with BRCA gene mutations may also benefit patients who have colorectal cancers
April 21st 2011
Exposure to air pollution at certain times in a woman's life can leave her more susceptible to premenopausal breast cancer